Vrije Universiteit Amsterdam

ctDNA-Based MRD Testing Shows Superior Prognostic Value in DLBCL First-Line Treatment

- Circulating tumor DNA-based minimal residual disease (ctDNA-MRD) testing using PhasED-Seq demonstrated strong prognostic value in patients with diffuse large B-cell lymphoma following first-line treatment. - Patients who were ctDNA-MRD negative at end of treatment achieved 85% 36-month progression-free survival compared to only 15% in MRD-positive patients. - The ctDNA-MRD testing proved more prognostic than traditional measures like PET-CT scans and International Prognostic Index scores for predicting treatment outcomes. - Eighty-six percent of patients who relapsed within 6 months were ctDNA-MRD positive, demonstrating high sensitivity for detecting early disease relapse.